SRD5A2 and Emerging Therapies in Androgen-Driven Disorders
January 2026
in “
Nature Reviews Urology
”
Research cited in this study
24 / 24 results
research Association of 5α-Reductase Inhibitors With Depression and Suicide: A Mini Systematic Review and Meta-Analysis
In this systematic review and meta-analysis, the authors found no statistically significant association between the use of 5α-reductase inhibitors and the risk of depression or suicide among over two million studied patients.
research Suicidal Risk Associated With Finasteride Versus Dutasteride Among Men Treated for Benign Prostatic Hyperplasia: Nationwide Cohort Study
This cohort study found no overall increased risk of suicidal behaviors with finasteride versus dutasteride in men aged 50 and older, but suggested potential risk for those with a history of mood disorders.
research Basics of Androgen Synthesis and Action
This review discusses the current understanding of androgen biosynthesis, mechanisms of action, and their roles in human biology, as well as related congenital and acquired disorders, but it reports no new research findings.
research Structure of Human Steroid 5α-Reductase 2 with the Anti-Androgen Drug Finasteride
This study provides the first crystal structure of the human SRD5A2 enzyme, revealing key insights into its function and inhibition which may aid future drug development.
research Post-Finasteride Syndrome: A Surmountable Challenge for Clinicians
This review discusses the evidence for post-finasteride syndrome as a condition potentially induced by finasteride and dutasteride, associating them with sexual dysfunction, depression, anxiety, and suicidal ideation in a subset of men, and reports no new clinical results.
research Intracrine Androgen Biosynthesis, Metabolism, and Action Revisited
This article discusses the role of androgens in metabolic and reproductive health and reports no new experimental results; the focus is on androgen receptor activation by testosterone and 5α-dihydrotestosterone.
research Effect of Dutasteride 0.5 mg/day in Men with Androgenetic Alopecia Recalcitrant to Finasteride
This study suggests that dutasteride may be a viable alternative for Korean men with androgenetic alopecia who do not respond to finasteride, as it improved hair density and thickness in most participants.
research Effects of 5-Alpha Reductase Inhibitors on Erectile Function, Sexual Desire, and Ejaculation
This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.
research 5α-Reductases in Human Physiology: An Unfolding Story
This review highlights the need for a deeper understanding of 5alpha-reductases and neuroactive steroids to reduce potential adverse effects of 5alpha-reductase inhibitors used for conditions like benign prostatic hyperplasia and androgenic alopecia, but reports no new clinical results.
research Mesotherapy Using Dutasteride-Containing Preparation in Treatment of Female Pattern Hair Loss: Photographic, Morphometric and Ultrastructural Evaluation
This study found that mesotherapy with a dutasteride-containing preparation improved hair growth indicators in female pattern hair loss better than saline, with minimal side effects and greater effectiveness in patients with shorter disease duration.
research The 5 Alpha-Reductase Isozyme Family: A Review of Basic Biology and Their Role in Human Diseases
This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.
research The Risks and Benefits of 5α-Reductase Inhibitors for Prostate Cancer Prevention
This review discusses the potential benefits and risks of 5α-reductase inhibitors in preventing prostate cancer and reports no new results.
research Reduced Levels of 5-Alpha Reductase 2 in Adult Prostate Tissue and Implications for BPH Therapy
This study found that methylation of the 5-AR 2 promoter region may lead to low or absent 5-AR 2 protein expression in some human adult prostate tissues.
research Estrogen and Androgen Signaling in the Pathogenesis of Benign Prostatic Hyperplasia
Hormonal interactions, especially involving DHT and estrogen, play a key role in BPH development and treatment.
research Differential Expression of Steroid 5α-Reductase Isozymes and Association with Disease Severity and Angiogenic Genes Predict Their Biological Role in Prostate Cancer
In this study, dutasteride more effectively reduced prostate cancer cell viability than finasteride in vitro, but did not significantly alter the angiogenic response.
research Identification of Finasteride Metabolites in Human Bile and Urine by High-Performance Liquid Chromatography/Tandem Mass Spectrometry
This study identified previously unknown phase I and phase II metabolites of finasteride in human bile and urine using a specialized bile collection technique and advanced mass spectrometry analysis.
research 5α-Reductase Type 2 Gene Variant Associations with Prostate Cancer Risk, Circulating Hormone Levels, and Androgenetic Alopecia
This study found that the SRD5A2 A49T A variant is associated with an increased risk of prostate cancer, lower circulating 3α‐diolG levels, and a decreased risk of baldness.
research The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
research Dihydrotestosterone and the Concept of 5-Alpha-Reductase Inhibition in Human Benign Prostatic Hyperplasia
This abstract reviews the role of finasteride and potential dual 5alpha-reductase inhibitors in treating benign prostatic hyperplasia, suggesting that dual inhibitors may offer greater DHT suppression and therapeutic advantages, while emphasizing the need for clinical evaluation.
research The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia
In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.
research The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia
Terazosin and finasteride effectively treat BPH, but combining them adds no extra benefit.
research Mechanism-Based Inhibition of Human Steroid 5α-Reductase by Finasteride: Enzyme-Catalyzed Formation of NADP-Dihydrofinasteride, a Potent Bisubstrate Analog Inhibitor
This study explains finasteride's high potency and specificity as a mechanism-based inhibitor for treating benign prostatic hyperplasia by detailing its interaction with human type 2 steroid 5α-reductase.
research Clinical Pharmacokinetics and Pharmacodynamics of Finasteride
Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.
research The Effect of Finasteride in Men with Benign Prostatic Hyperplasia
In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.
Related Community Posts Join
6 / 1000+ resultscommunity Androsterone as a Neurosteroid Replacement Strategy for 5α-Reductase Inhibitor–Associated Sexual and Affective Dysfunction
Androsterone may help with sexual and affective dysfunction from finasteride by replacing disrupted neurosteroids without increasing androgenic side effects. Controlled testing is needed to confirm its effectiveness and safety.
community Is there any role for topical DHT antagonists, or does a 5-AR inhibitor remove the need for them as therapy
Topical androgen receptor antagonists may not be necessary if 5-AR inhibitors like finasteride or dutasteride effectively reduce DHT levels. Combining a 5-AR inhibitor with a topical androgen antagonist could potentially enhance treatment, but oral use of androgen antagonists is too risky due to severe side effects.
community Androgen degraders for hair loss
The conversation discusses androgen receptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.
community FCE 28260: A Forgotten 5α-Reductase Inhibitor
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
community A better treatment would be a localized 5ar inhibitor that breaks down when it enters blood or leaves hair follicle
The conversation discusses the need for a localized 5-alpha reductase inhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.
community Best available SARD right now?
The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.
Similar Research
5 / 1000+ results
research Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men
This review discusses the negative health impacts of testosterone deficiency and the potential adverse effects of 5α-reductase inhibitors, emphasizing the need for patient-physician discussions regarding these treatments.
research Experimental and early investigational drugs for androgenetic alopecia
This review discusses current and emerging therapeutic strategies for androgenetic alopecia, noting limited evidence but suggesting areas such as prostaglandin analogs, PRP, and progenitor cell therapies as promising future directions.
research 5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes
In this study, manipulation of the enzyme 5α-reductase type 2 in human hepatocytes altered lipogenesis, suggesting clinical implications for patients using 5α-reductase inhibitors by affecting glucocorticoid action on hepatic lipid metabolism.
research Precision therapeutics in non-scarring alopecia: a systemic genomic and pathway-based framework for targeted interventions
This review synthesizes recent research to propose a precision framework for treating androgenetic alopecia and alopecia areata based on genetic insights and pathway biology, highlighting the roles of androgen-receptor signaling, immune dysregulation, and emerging therapies like regenerative medicine and AI-assisted diagnostics.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.